TNIK Antibody (C-1): sc-377215

TNIK Antibody (C-1) is a mouse monoclonal IgG2b kappa light chain antibody that detects TNIK protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). anti-TNIK antibody (C-1) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. TNIK, also known as TRAF2 and NCK-interacting protein kinase, is a critical serine/threonine kinase that plays a significant role in cellular signaling pathways, particularly in response to environmental stress. TNIK is composed of 1,360 amino acids and features a protein kinase domain, which is essential for catalytic activity. TNIK is expressed ubiquitously, with highest levels found in brain, heart, and skeletal muscle, indicating importance in various physiological processes. TNIK is involved in phosphorylation of target proteins, a key regulatory mechanism that influences cell division, apoptosis, and cytoskeletal dynamics. TNIK exists in eight isoforms generated through alternative splicing, which may contribute to functional diversity and regulatory roles in different cellular contexts. TNIK monoclonal antibody (C-1) enables researchers to gain valuable insights into complex signaling networks mediated by TNIK and implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TNIK Antibody (C-1) References:

1. Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer.  |  Masuda, M., et al. 2015. Pharmacol Ther. 156: 1-9. PMID: 26542362
2. TNIK inhibition abrogates colorectal cancer stemness.  |  Masuda, M., et al. 2016. Nat Commun. 7: 12586. PMID: 27562646
3. Emergence of TNIK inhibitors in cancer therapeutics.  |  Yamada, T. and Masuda, M. 2017. Cancer Sci. 108: 818-823. PMID: 28208209
4. Effect of TNIK upregulation on JQ1-resistant human colorectal cancer HCT116 cells.  |  Takahashi, C., et al. 2020. Biochem Biophys Res Commun. 530: 230-234. PMID: 32828291
5. TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.  |  Torres-Ayuso, P., et al. 2021. Cancer Discov. 11: 1411-1423. PMID: 33495197
6. TNIK influence the effects of antipsychotics on Wnt/β-catenin signaling pathway.  |  Yuan, R., et al. 2021. Psychopharmacology (Berl). 238: 3283-3292. PMID: 34350475
7. LKB1 loss promotes colorectal cancer cell metastasis through regulating TNIK expression and actin cytoskeleton remodeling.  |  Hu, G., et al. 2023. Mol Carcinog. 62: 1659-1672. PMID: 37449799
8. TNIK regulation of interferon signaling and endothelial cell response to virus infection.  |  Chau, KM., et al. 2023. Front Cardiovasc Med. 10: 1213428. PMID: 38264262
9. TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy.  |  Nguyen, T., et al. 2024. Mol Cancer Ther.. PMID: 38670554
10. TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy.  |  Nguyen, T., et al. 2024. Mol Cancer Ther. OF1-OF11. PMID: 38853421

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TNIK Antibody (C-1) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-TNIK Antibody (C-1) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TNIK Antibody (C-1) Specifications

Alternate Product Name: TRAF2 NCK Interacting Kinase

Product Clone Name: C-1

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 844-922

Epitope Target: TNIK

Epitope Species: human

Product Reactivity/Detection: TNIK

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for TNIK Antibody (C-1): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred TNIK antibody is TNIK Antibody (53): sc-136103.